Login to Your Account



Other News To Note


Monday, October 31, 2011

• Atlab Pharma SAS, of Nantes, France, and BZL Biologics LLC, of New York, entered a sublicense agreement to develop (177)Lu-J591 as a prostate cancer treatment. The agreement includes exclusive rights to manufacture, develop and commercialize the radiopharmaceutical worldwide, as well as a joint Phase IIb/III program. Atlab will fund certain product development and clinical trials, but no financial terms were disclosed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription